Previous close | 43.97 |
Open | 43.63 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 4000 |
Day's range | 43.50 - 44.46 |
52-week range | 41.45 - 56.32 |
Volume | |
Avg. volume | 21,858,740 |
Market cap | 248.894B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | 8.11 |
EPS (TTM) | 5.47 |
Earnings date | 01 May 2023 - 05 May 2023 |
Forward dividend & yield | 1.64 (3.73%) |
Ex-dividend date | 26 Jan 2023 |
1y target est | 52.96 |
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
Wells Fargo Managing Director Mohit Bansal joins Yahoo Finance Live to discuss pharmaceutical earnings amid COVID uncertainty, the impact of diabetic weight loss drugs on the market, and the outlook for drugmakers.
Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.